Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Schmid, Peter; Adams, Sylvia; S. Rugo, Hope; Schneeweiss, Andreas; H. Barrios, Carlos; Iwata, Hiroji; Dièras, Véronique; Hegg, Roberto; Im, Seock‐Ah; S. Wright, Gail; Henschel, Volkmar; Molinero, Luciana; Yuet Ching Hui, Jane; Funke, Roel; Husain, Amreen; P. Winer, Eric; Loi, Sherene; A. Emens, Leisha

doi:10.1056/nejmoa1809615

Public

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Published in New England Journal of Medicine • Oct 20, 2018

Authors:

Peter Schmid

Sylvia Adams

Hope S. Rugo

Abstract

BACKGROUND: Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity ...

Subject

Atezolizumab

Triple-negative breast cancer

Paclitaxel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!